180 Life Sciences (ATNF) Stock Price, News & Analysis

Company Overview

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $0.96 to $1.02
• 50-Day Range: $1.03 to $1.60
• 52-Week Range: $0.95 to $17.75
• Volume: 24,562 shs
• Average Volume: 791,300 shs
• Market Capitalization: $3.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATNF Stock Analysis - Frequently Asked Questions

How have ATNF shares performed this year?

180 Life Sciences' stock was trading at $1.82 at the beginning of the year. Since then, ATNF shares have decreased by 44.5% and is now trading at $1.01.
View the best growth stocks for 2025 here.

When did 180 Life Sciences' stock split?

Shares of 180 Life Sciences reverse split on Wednesday, February 28th 2024. The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are 180 Life Sciences' major shareholders?

Top institutional shareholders of 180 Life Sciences include Anson Funds Management LP (7.08%) and Rathbones Group PLC (2.20%). Insiders that own company stock include James N Woody, Jr Donald A Mcgovern, Pamela G Marrone and Ozan Pamir.
View institutional ownership trends.

How do I buy shares of 180 Life Sciences?

Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 180 Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 180 Life Sciences investors own include Meta Platforms (META), NIO (NIO), Enterprise Products Partners (EPD), HubSpot (HUBS), Netflix (NFLX), Plug Power (PLUG).

Company Calendar

• Today: 3/31/2025
• Next Earnings (Estimated): 4/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATNF
• CIK: 1690080
• Web: www.kblmerger.com
• Phone: (650) 507-0669
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -558.93%
• Return on Assets: -54.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.24) per share
• Price / Book: -4.29

Miscellaneous

• Outstanding Shares: 3,177,000
• Free Float: 3,172,000
• Market Cap: $3.27 million
• Optionable: No Data
• Beta: 0.20